drugset / Trial / NCT05248776
Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes
Phase 2
Unknown
80 enrolled
Celon Pharma SA
National Center for Research and Development, Poland · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The planned study is to evaluate the efficacy, safety and pharmacokinetic (PK) properties of CPL207280 after multiple (14 days) administration in patients with type 2 diabetes.
Timeline
- Start
- 2022-01-21
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPL207280 | Unknown | 60 mg | — |
| Subject | CPL207280 | Unknown | 120 mg | — |
| Subject | CPL207280 | Unknown | 240 mg | — |
| Subject | CPL207280 | Unknown | 480 mg | — |